CannabisNewsWire
Editorial Coverage: Experiments with next-generation delivery
systems appear certain to lead to better cannabis-based
products.
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)
(LXRP
Profile) has recently seen spectacular improvements in
the effectiveness of cannabinoids thanks to its proprietary
chemical delivery treatment. GW Pharmaceuticals Plc
(NASDAQ: GWPH) (OTC: GWPRF), which has won widespread
praise for its innovative medical work, has seen good trial results
for a new treatment for seizures. Tilray Inc. (NASDAQ:
TLRY) is supporting studies into the uses of cannabinoids
to treat behavioral problems and HIV. MariMed Inc. (OTCQB:
MRMD) has set up a subsidiary focused on CBD, currently
the highest-profile cannabinoid product. Cronos Group Inc.
(NASDAQ: CRON) (TSX: CRON) has established a new research
lab to develop devices for CBD consumption.
- Currently, cannabis medicines are poorly absorbed by the
body.
- Delivery challenges increase costs and reduce
effectiveness.
- Select companies are working on better delivery systems.
- Others are working on new medicines so that cannabinoids can
improve more lives.
To view an infographic of this editorial, click here.
The Cannabinoid Waste Conundrum
The popularity of cannabinoid products — those containing active
ingredients from cannabis — has created a challenge for producers.
While these producers are extracting larger volumes of CBD from
cannabis and hemp, much of the precious ingredient goes to waste:
the human body only absorbs a small fraction of these molecules
because of delivery system limitations and human physiology.
This delivery challenge causes several problems. Manufacturers
must comply with regulations limiting the amount of active
cannabinoid ingredients, but consumers may not be able to obtain
the effect or benefit they are seeking, even when needed to
overcome serious medical conditions. People could end up consuming
more cannabis than they would otherwise, which is both expensive
and ill-advised. And in an age when the waste of human society is
ravaging the environment, it means that the cannabis industry may
also be doing unneeded damage to the environment.
But thanks to the fast pace of cannabis research, a solution may
be on the horizon.
Improving the Delivery of Cannabinoids
Across the industry, researchers are looking for ways to more
effectively deliver CBD into the human body. Thanks to their latest
breakthroughs, the scientists at Lexaria
Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) appear to be
leading the way.
A biotech company based in British Columbia, Lexaria is
currently focusing on its proprietary DehydraTECH(TM) technology.
This unique technology has been developed to make medicinal
compounds more suitable for human consumption in a number of ways.
By combining molecules such as CBD with fatty acids at a molecular
level, DehydraTECH makes it easier for the CBD to cross the body’s
internal barriers. Higher levels of CBD are absorbed, and they are
absorbed more quickly.
Consumers need to know this: the quantity of CBD, or any other
drug, in the bottle is unimportant. What matters is how much of
that CBD actually reaches the bloodstream — and even more
importantly — how much reaches the brain.
Most CBD sold in CBD-infused products in America today does not
reach the bloodstream. CBD mixed in water and fed to animals
demonstrated the incredible power of DehydraTECH. Results announced
in May showed that DehydraTECH, in combination with generic
nanotech techniques, delivered CBD to the
brain 1,137% more efficiently than existing industry
formulations. In addition, Lexaria’s patented DehydraTECH delivered
CBD into the bloodstream in just two minutes and delivered as much
CBD in 15 minutes as generic doses did in 60 minutes.
Not content with these sorts of results, the company has been
working on improving the power of DehydraTECH through a new
second-generation version called Enhanced
DehydraTECH. Lexaria’s Enhanced DehydraTECH showed remarkable
properties in crossing the blood-brain-barrier, delivering 1,937%
more CBD into the brain than a generic industry formulation. It
also delivered between 717% and 1,098% more CBD into the
bloodstream than generic CBD formulations.
Lexaria’s technological advances make it possible to manufacture
capsules and edible products that deliver CBD and THC more
effectively than ever before.
Satisfying Customers and Regulators
This vastly superior delivery performance holds promise to
radically change the CBD industry, at a time when the sector is
already going through huge change and growth.
On one level, the benefits of technology such as that being
developed by Lexaria are obvious. A more efficient delivery system
can do one of two things: it can make the same dose of a drug or
vitamin more effective, or it can allow the same consumer effect to
be achieved with a smaller dose.
The latter approach may have the widest impact and certainly has
potential to shift prices. Recent legal changes in Canada and the
United States have led to a surge in demand for CBD, a demand that
suppliers have been unable to meet. With demand
for CBD outstripping supply and a production process that involves
complex technical steps, the price of CBD is relatively high. But
if companies can make products that are just as effective but use
smaller amounts of CBD, they can reduce their production costs and
provide more products with the same raw resources. This change
would allow companies to meet currently unmet demand and reduce
prices, thus benefitting both the customers and the industry.
There’s also a less-obvious factor, one that industry outsiders
might not consider but that companies such as Lexaria are acutely
aware of. With the legalization of cannabis across Canada and hemp
in the United States, regulators are stepping in to control the
production, sale and dosage amounts of CBD or THC products. Limits
are being set on how much CBD or THC a product can contain.
Improved delivery systems such as DehydraTECH allow companies to
produce more effective products within the same legal limits.
Customers can experience the highest benefit from their products
while everyone stays inside the law.
Beyond CBD?
But while CBD is proving a profitable testing ground for
DehydraTECH, the impact of this first-of-its-kind delivery system
could potentially go far beyond this, extending into the wider
medical sector.
Recent research results have shown that DehydraTECH is effective
in delivering both cannabinoids and nicotine into brain tissue,
thus improving the speed and effectiveness of these ingredients.
The delivery system also comes with a fast-on/fast-off element, in
which the effect of the drug both starts and ends quickly and
clearly, providing better control over the use of the products in
which drugs are used. DehydraTECH is being evaluated by the largest
nicotine company in America for products utilizing oral delivery,
bypassing the known disease conditions associated with current
pulmonary delivery.
As a result, Lexaria’s technology already has potential medical
benefits because it can be used to deliver CBD- and THC-based
medicines, in addition to its applications as a solution to
cigarette use. But what if it could do more?
Since DehydraTECH has been shown to work with multiple
molecules, people are asking if it could be used with central
nervous system drugs. By delivering drugs quickly and efficiently
across the blood-brain-barrier, this innovative delivery system
could enhance the speed and effectiveness of a wide range of drugs
and potentially usher in a new era of treatment for a wide range of
debilitating diseases. Lexaria has quietly filed patent applications for innovation in treatment
options related to central nervous system diseases such as
Parkinson’s and Alzheimers.
Experimenting with Cannabis
Given the importance of cannabinoids in treating some of these
debilitating diseases, improved delivery systems already have clear
medical advantages. Among the companies applying cannabinoids to
life-changing medicines is GW Pharmaceuticals Plc (NASDAQ:
GWPH) (OTC: GWPRF). With more than 20 years of research in
the cannabis sector, GW is a global leader in developing
cannabinoid medicines and was named one of Time Magazine’s
50 genius companies for this work. The company recently announced
successful clinical trials of EPIDIOLEX, in
which this CBD drug was used to reduce the frequency of seizures
associated with tubular sclerosis complex.
Tilray Inc. (NASDAQ: TLRY), a world-leading
cannabis company based in Canada, has been working to address the
shortage of cannabis and CBD, investing $32.6
million in an expansion of its cultivation and manufacturing
facilities. But the company isn’t just working on meeting current
needs. Tilray is providing support to two
clinical studies that could lead cannabinoids to transform more
lives for the better. Through studies like these, the use of
cannabinoids is spreading beyond its traditional territory of pain
and nausea management.
MariMed Inc. (OTCQB: MRMD), a multistate
cannabis company, has been improving the efficiency of its
operations through vertical integration and the addition of new
product lines, allowing it to more effectively deliver cannabis
products to a wide range of customers. At the start of this year,
the company established a subsidiary focused
on CBD in response to rising sales and the changed legal status
of hemp manufacturing in the US.
Lexaria’s work on DehyrdaTECH isn’t the only area where the
interests of cannabis and tobacco are merging. Cronos Group
Inc. (NASDAQ: CRON) (TSX: CRON), a global cannabinoid
company, has had its fortunes and its profile improved by an
investment of C$2.4 billion from tobacco giant
Altria. The company’s growth has also allowed it to establish a
new global research and design center, Cronos
Device Labs, in Israel. There, the company will work on devices
specifically designed for the consumption of CBD.
As the technology around cannabis improves, so will the
efficiency and effectiveness of cannabinoid products, lowering
prices and improving outcomes for patients around the world.
For more information on Lexaria Bioscience Corp., visit Lexaria
Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides
(1) access to our news aggregation and syndication servers, (2)
CannabisNewsBreaks that summarize
corporate news and information, (3) enhanced press release
services, (4) social media distribution and optimization services,
and (5) a full array of corporate communication solutions. As a
multifaceted financial news and content distribution company with
an extensive team of contributing journalists and writers, CNW is
uniquely positioned to best serve private and public companies that
desire to reach a wide audience of investors, consumers,
journalists and the general public. CNW has an ever-growing
distribution network of more than 5,000 key syndication outlets
across the country. By cutting through the overload of information
in today’s market, CNW brings its clients unparalleled visibility,
recognition and brand awareness. CNW is where news, content and
information converge.
Receive Text Alerts
from CannabisNewsWire: Text "Cannabis" to
21000
For more information please visit https://www.CannabisNewsWire.com and
or https://CannabisNewsWire.News
Please see full terms of use and disclaimers on the
CannabisNewsWire website applicable to all content provided by CNW,
wherever published or re-published: http://CNW.fm/Disclaimer
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article
and content set forth above. References to any issuer other than
the profiled issuer are intended solely to identify industry
participants and do not constitute an endorsement of any issuer and
do not constitute a comparison to the profiled issuer. The
commentary, views and opinions expressed in this release by CNW are
solely those of CNW. Readers of this Article and content agree that
they cannot and will not seek to hold liable CNW for any investment
decisions by their readers or subscribers. CNW is a news
dissemination and financial marketing solutions provider and is NOT
registered broker-dealers/analysts/investment advisers, hold no
investment licenses and may NOT sell, offer to sell or offer to buy
any security.
The Article and content related to the profiled company
represent the personal and subjective views of the Author, and are
subject to change at any time without notice. The information
provided in the Article and the content has been obtained from
sources which the Author believes to be reliable. However, the
Author has not independently verified or otherwise investigated all
such information. None of the Author, CNW, or any of their
respective affiliates, guarantee the accuracy or completeness of
any such information. This Article and content are not, and should
not be regarded as investment advice or as a recommendation
regarding any particular security or course of action; readers are
strongly urged to speak with their own investment advisor and
review all of the profiled issuer’s filings made with the
Securities and Exchange Commission before making any investment
decisions and should understand the risks associated with an
investment in the profiled issuer’s securities, including, but not
limited to, the complete loss of your investment.
CNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. “Forward-looking statements” describe future expectations,
plans, results, or strategies and are generally preceded by words
such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”.
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and CNW undertakes no
obligation to update such statements.
Source:
CannabisNewsWire
Contact:
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net
Cronos (NASDAQ:CRON)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cronos (NASDAQ:CRON)
Historical Stock Chart
From Apr 2023 to Apr 2024
